Skip to search formSkip to main contentSkip to account menu

Satigrel

Known as: 4-Pentenoic acid, 4-cyano-5,5-bis(4-methoxyphenyl)-, 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

E 5510

Broader (2)

Fatty Acids, MonounsaturatedPlatelet Aggregation Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
Satigrel, a new antiplatelet agent, inhibits platelet accumulation in prosthetic arterial grafts.
1996
1996
Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase…
Satigrel (E5510, 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid) is a potent inhibitor of platelet aggregation. Like… 
1996
1996
Clinical evaluation of satigrel in intermittent claudicators.
OBJECTIVE Satigrel is a new antiplatelet agent which was previously shown to inhibit platelet aggregation and have an anti… 
1994
1994
Effect of Satigrel (E5510), a Novel Antiplatelet Agent, on Platelet Function and the Coagulation-Fibrinolytic System in Peripheral Arterial Occlusive Disease
A novel antiplatelet agent, satigrel (E5510), was administered to 9 patients with arteriosclerosis obliterans (ASO) and 6… 
1994
1994
慢性末梢動脈閉塞症における抗血小板薬 satigrel (E5510) の血小板および血液凝固線溶系に及ぼす影響
1993
1993
Inhibitory effects of a novel antiplatelet agent, E5510, on collagen-induced platelet-derived growth factor release and aggregation of human platelets in vitro.
E5510, 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid, is a new anti-platelet-aggregation agent under development. We examined… 
1991
1991
A new anti-platelet drug, E5510, has multiple suppressive sites during receptor-mediated signal transduction in human platelets.
The mode of action of E5510, 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid, which has very potent anti-platelet activities… 
1990
1990
Non-heparin hemodialysis with oral administration of newly developed antiplatelet agent.
Non-heparin hemodialysis (HD) was successfully done in anuric dogs with the oral administration of a newly developed antiplatelet… 
1990
1990
Determination of 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid in human plasma and platelets by gas chromatography-mass spectrometry.
1987
1987
Pharmacological properties of the novel anti-platelet aggregating agent 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid.
Various pharmacological properties of a new antiplatelet aggregating agent, 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid (E… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)